LY 3154207

Drug Profile

LY 3154207

Alternative Names: LY3154207

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antiparkinsonians
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 09 Nov 2017 Phase-II clinical trials in Parkinson's disease in Puerto Rico, Canada, USA (PO) (NCT03305809)
  • 12 Oct 2017 Eli Lilly plans a phase II trial for Parkinson's disease (NCT03305809)
  • 03 Mar 2017 Eli Lilly completes a phase I trial in Parkinson's disease in USA (NCT02562768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top